HCPCS Level II Q4199: Cygnus Matrix, Per Square Centimeter - OpenPayer

Summary & Overview

HCPCS Level II Q4199: Cygnus Matrix, Per Square Centimeter

HCPCS Level II code Q4199 designates the Cygnus matrix, billed per square centimeter as an add-on to a primary procedure. The code captures use of a biologic matrix product applied to a surgical or wound site to support tissue repair or regeneration. Nationally, accurate coding for add-on biologic materials affects procedure-level reporting, bundling decisions, and device utilization tracking across payers.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the Cygnus matrix, common sites of service where the product is applied, and the payer landscape addressed. The publication outlines typical billing considerations for add-on biologic matrices, highlights benchmarks for utilization and coding prevalence where available, and summarizes recent policy or reimbursement updates relevant to add-on biologic materials.

This resource is intended for revenue cycle professionals, clinical coding staff, and policy analysts seeking a concise reference on HCPCS Level II code Q4199, its clinical use, and implications for claims reporting and payer coordination at a national level.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareQ4199HCPCS Level IIbiologic matrixadd-on codewound caresurgical graftrevenue cyclemedical coding

Billing Code Overview

HCPCS Level II code Q4199 describes the Cygnus matrix, billed per square centimeter as an add-on, list separately in addition to the primary procedure. This product is a biologic matrix used to support tissue repair or regeneration and is reported in addition to the primary surgical or wound procedure when applied to the treated area.

Service type: Biologic graft/matrix application

Typical site of service: Operative suite, ambulatory surgery center, or wound care clinic

Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and detailed service line information.

Clinical & Coding Specifications

Clinical Context

A patient with a full-thickness or complex soft-tissue wound on the lower extremity following debridement presents for placement of a Cygnus dermal regeneration matrix as an adjunct to definitive wound coverage. The typical patient is an adult with a chronic non-healing ulcer (for example, diabetic foot ulcer or venous stasis ulcer) or an acute traumatic soft-tissue defect where primary closure is not possible. The clinical workflow includes wound assessment and debridement in the operating room or procedure suite, measurement of the wound surface area in square centimeters, placement of the Cygnus matrix to provide a scaffold for dermal regeneration, securement with appropriate fixation and dressing, and planned follow-up visits for dressing changes and evaluation of integration prior to any subsequent autografting if needed. Documentation includes wound dimensions, indication, description of matrix placement per square centimeter billed using Q4199 as an add-on to the primary procedure, and any applicable modifiers reflecting operative circumstances or payer requirements.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no specific modifier applies and payer requires a default code indicator.

HCPCS Q5106: Epoetin alfa-epbx (Retacrit) 1000-unit Injection

HCPCS-Q4386-TRIFACIAL-ACCESS-PER-SQ-CM-ADD-ON

HCPCS Q4386: Trifacial Access, Per Square Centimeter (Add-on)

HCPCS-Q4153-DERMAL-DRESSINGS-PER-SQUARE-CENTIMETER

HCPCS Level II Q4153: Dermavest and Plurivest, per sq cm

HCPCS-Q4183-SURGIGRAFT-PER-SQ-CM-ADD-ON

HCPCS Q4183: Surgigraft, per square centimeter (add-on)

HCPCS-Q4440-CURAMATRIX-WOUND-MATRIX-PER-SQ-CM

HCPCS Q4440: Curamatrix Per Square Centimeter, Add-On

HCPCS-Q2056-CILTACABTAGENE-AUTOLEUCEL-CAR-T-THERAPY-BCMA

HCPCS Q2056: Ciltacabtagene Autoleucel CAR T-Cell Therapy

HCPCS-Q0164-PROCHLORPERAZINE-ORAL-ANTI-EMETIC-CHEMO-SUBSTITUTE

HCPCS Q0164: Prochlorperazine 5 mg Oral Anti-Emetic for Chemotherapy

HCPCS-Q0478-VEHICLE-POWER-ADAPTER-VENTRICULAR-ASSIST-DEVICE

HCPCS Q0478: Power Adapter for Vehicle Use with Ventricular Assist Device

HCPCS-Q4213-ASCENT-0-5-MG

HCPCS Q4213: Ascent, 0.5 mg

HCPCS-Q4045-SHORT-LEG-PLASTER-SPLINT-ADULT

HCPCS Q4045: Short Leg Plaster Splint, Adult (11+)

Showing 1–10 of 629

22

Taxonomy Code	Specialty	Notes
`207L00000X`	Plastic Surgery	Common specialty performing dermal matrix placement, reconstruction and grafting.
`207P00000X`	General Surgery	Often performs wound debridement and placement of dermal matrices in traumatic or complex wounds.
`207V00000X`	Podiatry	Frequently manages lower extremity wounds and performs matrix placement for foot and ankle defects.
`2080P0217X`	Wound Care Specialist (Osteopathic/Family Medicine with wound focus)	Performs wound management, application, and follow-up of biologic matrices.
`208D00000X`	Dermatology	May perform matrix application for complex skin defects and reconstruction.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L97.421`	Non-pressure chronic ulcer of right heel and midfoot with fat layer exposed	Represents a typical chronic diabetic foot ulcer where dermal matrix application may be indicated.
`L97.429`	Non-pressure chronic ulcer of unspecified foot with fat layer exposed	Another variant of lower extremity ulcer commonly treated with dermal matrices.
`I83.019`	Varicose veins of unspecified lower extremity with ulcer of calf	Venous stasis ulcers often require advanced wound therapies including dermal matrices.
`S81.811A`	Laceration without foreign body of right knee, initial encounter	Acute traumatic soft-tissue defects that may require dermal matrix placement after debridement.
`T79.A21A`	Traumatic compartment syndrome of right lower leg, initial encounter	Severe soft-tissue injury scenarios where dermal regeneration matrices can be part of reconstruction.
`E11.621`	Type 2 diabetes mellitus with foot ulcer	Diabetes-related wounds are a primary indication for advanced biologic matrices to promote healing.
`L89.154`	Pressure ulcer of left heel, stage 4	Deep pressure injuries frequently require dermal substitutes as part of reconstructive planning.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`11042`	Debridement, subcutaneous tissue, first 20 sq cm or less	Commonly performed before application of a dermal matrix to remove necrotic tissue and prepare the wound bed.
`15271`	Application of skin substitute graft to trunk, arms, legs; first 100 sq cm or less	May be used when a biologic skin substitute or grafting procedure is performed in conjunction with or following matrix placement.
`15777`	Dermal substitute, xenograft or synthetic; per 1 sq cm	Related category for dermal substitutes; used in workflows where additional or alternative dermal products are applied.
`13160`	Secondary closure of wound, extensive or complicated	May be used later in the course when closure is achieved after matrix integration and wound contraction.
`97605`	Negative pressure wound therapy (NPWT) first 55 sq cm or less, including topical application	Often applied after matrix placement to bolster adherence and promote integration of the dermal matrix.

OpenPayer